Lucid Diagnostics Inc’s recent filing unveils that its Director Matheis Dennis acquired Company’s shares for reported $0.24 million on May 20 ’25. In the deal valued at $1.29 per share,187,098 shares were bought. As a result of this transaction, Matheis Dennis now holds 187,098 shares worth roughly $0.19 million.
Then, Matheis Dennis bought 129,684 shares, generating $171,520 in total proceeds. Upon buying the shares at $1.32, the Director now owns 316,782 shares.
Before that, Matheis Dennis bought 33,218 shares. Lucid Diagnostics Inc shares valued at $43,795 were divested by the Director at a price of $1.32 per share. As a result of the transaction, Matheis Dennis now holds 350,000 shares, worth roughly $0.35 million.
Ascendiant Capital Markets initiated its Lucid Diagnostics Inc [LUCD] rating to a Buy in a research note published on December 27, 2021; the price target was $16. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in early November with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering LUCD with “an Overweight” recommendation on November 08, 2021. BTIG Research started covering the stock on November 08, 2021. It rated LUCD as “a Buy”.
Price Performance Review of LUCD
On Friday, Lucid Diagnostics Inc [NASDAQ:LUCD] saw its stock jump 2.19% to $1.0. Over the last five days, the stock has lost -9.91%. Lucid Diagnostics Inc shares have risen nearly 26.60% since the year began. Nevertheless, the stocks have risen 22.14% over the past one year.
How much short interest is there in Lucid Diagnostics Inc?
A steep rise in short interest was recorded in Lucid Diagnostics Inc stocks on 2025-07-15, growing by 3.13 million shares to a total of 4.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 1.66 million shares. There was a rise of 65.43%, which implies that there is a positive sentiment for the stock.
